Qiagen (NYSE:QGEN) Position Boosted by Man Group plc

Man Group plc boosted its position in Qiagen (NYSE:QGEN - Free Report) by 17.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 483,357 shares of the company's stock after buying an additional 72,239 shares during the quarter. Man Group plc owned approximately 0.22% of Qiagen worth $21,524,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Groupama Asset Managment grew its holdings in Qiagen by 8,074.0% during the fourth quarter. Groupama Asset Managment now owns 31,817,740 shares of the company's stock valued at $1,416,844,000 after purchasing an additional 32,216,761 shares during the period. Norges Bank bought a new position in shares of Qiagen in the fourth quarter valued at about $181,529,000. Massachusetts Financial Services Co. MA increased its position in Qiagen by 9.5% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 25,319,332 shares of the company's stock worth $1,127,470,000 after acquiring an additional 2,202,040 shares during the period. Caisse Des Depots ET Consignations acquired a new stake in Qiagen during the fourth quarter worth about $53,991,000. Finally, Barclays PLC boosted its stake in shares of Qiagen by 170.6% in the 3rd quarter. Barclays PLC now owns 1,849,004 shares of the company's stock valued at $84,259,000 after purchasing an additional 1,165,594 shares in the last quarter. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Qiagen Stock Performance

Qiagen stock traded down $0.08 during mid-day trading on Tuesday, reaching $42.72. 911,934 shares of the company were exchanged, compared to its average volume of 1,145,934. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.09 and a current ratio of 3.61. The firm's 50-day simple moving average is $41.03 and its two-hundred day simple moving average is $41.82. The firm has a market cap of $9.50 billion, a PE ratio of 118.95, a price-to-earnings-growth ratio of 2.39 and a beta of 0.67. Qiagen has a twelve month low of $37.63 and a twelve month high of $49.30.

Qiagen (NYSE:QGEN - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.55 EPS for the quarter, beating analysts' consensus estimates of $0.50 by $0.05. Qiagen had a return on equity of 13.92% and a net margin of 4.23%. The business had revenue of $483.46 million during the quarter, compared to the consensus estimate of $465.66 million. During the same quarter in the previous year, the business earned $0.44 earnings per share. The business's revenue for the quarter was up 5.2% on a year-over-year basis. Equities analysts predict that Qiagen will post 2.26 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently weighed in on QGEN shares. Redburn Atlantic lowered shares of Qiagen from a "buy" rating to a "neutral" rating in a research note on Friday, April 4th. Robert W. Baird increased their price target on shares of Qiagen from $42.00 to $43.00 and gave the stock a "neutral" rating in a report on Monday, April 21st. UBS Group decreased their price objective on shares of Qiagen from $50.00 to $48.00 and set a "neutral" rating on the stock in a research report on Friday, February 7th. Baird R W cut shares of Qiagen from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, February 19th. Finally, StockNews.com upgraded shares of Qiagen from a "buy" rating to a "strong-buy" rating in a research report on Thursday, May 15th. Seven equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $48.42.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.